Disc Medicine (IRON) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability
2. 02We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future
3. 03future accounting pronouncements or changes in our accounting policies
4. 04We have no products approved for commercial sale and have not generated any revenue from product sales
5. 05maintain a continued acceptable safety profile of our products following approval
6. 06Our existing and any future indebtedness could adversely affect our ability to operate our business
7. 07We may need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts
8. 08the potential additional expenses attributable to adjusting our development plans (including any supply related matters) to any public health crises
9. 09Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates

Risks Related to the Discovery and Development of Our Product Candidates

1. 10We have not yet progressed any product candidates into a Phase 3 clinical trial and may be unable to successfully complete any additional clinical trials for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development
2. 11Our programs are focused on the development of therapeutics for patients with hematologic diseases, which is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates is novel and may never lead to approved or marketable products
3. 12Clinical product development involves a lengthy and expensive process, with an uncertain outcome
4. 13Interim, top-line, initial and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data
5. 14We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates
6. 15regulators may revise the requirements for approving our product candidates, or such requirements may not be as anticipated
7. 16If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
8. 17In addition, some of our competitors have ongoing clinical trials for product candidates that are intended to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors’ product candidates
9. 18factors we may not be able to control, including the impacts of any public health crises, that may limit patients, principal investigators or staff or clinical site availability
10. 19Our clinical trials or those of our future collaborators may reveal significant adverse events not seen in prior preclinical studies or clinical trials and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates
11. 20Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval or discovery of unknown or unanticipated adverse effects on safety or efficacy
12. 21We have conducted and are currently conducting clinical trials for bitopertin in Australia and may in the future conduct additional clinical trials of our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials
13. 22it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio
14. 23If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for any of our product candidates, we will not be able to commercialize, or will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired
15. 24the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval
16. 25A public health crisis, pandemic, epidemic, or outbreak of an infectious or highly contagious disease, may materially and adversely affect our business and financial results and could cause a disruption to the development of our product candidates

Risks Related to Commercialization

1. 26We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
2. 27If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability could be materially adversely affected
3. 28If our current product candidates or any future product candidates do not achieve broad market acceptance, the revenue that we generate from our sales may be limited, and we may never become profitable
4. 29potential product liability claims
5. 30We may not be successful in addressing these or other factors that might affect the market acceptance of our product candidates. Failure to achieve widespread market acceptance of our product candidates would materially harm our business, financial condition and results of operations
6. 31injunctions or the imposition of civil or criminal penalties

Risks Related to Our Reliance on Third Parties

1. 32form relationships with other entities, some of which may be our competitors
2. 33We might not realize the anticipated benefits of our current collaborations with Mabwell or NIH, or any other collaborations we enter into in the future
3. 34collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates
4. 35We have established collaborations with Mabwell and NIH and may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans
5. 36biotechnology companies, such as our collaborations with Mabwell and NIH, for the development and potential commercialization of those product candidates
6. 37the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved
7. 38Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of CDMOs that operate under cGMP regulations and that might be capable of manufacturing for us
8. 39The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole sources of supply, and the loss of any of these suppliers could significantly harm our business

Risks Related to Our Intellectual Property

1. 40duration of such protections that we expect for our product candidates, if approved, could affect our decision on whether to market the products in a particular country or countries or could otherwise have an adverse impact on our revenue or results of operations
2. 41If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed
3. 42to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us
4. 43We may initiate, become a defendant in or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful
5. 44Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities
6. 45methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods
7. 46there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock
8. 47We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties
9. 48If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
10. 49the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners
11. 50Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates
12. 51We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates
13. 52Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Government Regulation

1. 53Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
2. 54We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
3. 55We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
4. 56We have received rare pediatric disease designation for bitopertin. However, a marketing application for bitopertin, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher
5. 57possible that the FDA's authority to grant rare pediatric disease designation or award rare pediatric disease priority review vouchers will be further extended by Congress
6. 58If we are not able to obtain accelerated approval for a product candidate, we may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, full FDA approval, if received at all
7. 59If our drug product candidates or any of our future drug product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of our competing products
8. 60If approved, our investigational products regulated as biologics may face competition from biosimilars or interchangeable products approved through an abbreviated regulatory pathway
9. 61The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict
10. 62The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
11. 63Healthcare reform measures may have a material adverse effect on our business and results of operations
12. 64The U.S. American Rescue Plan Act of 2021, which eliminates the statutory Medicaid drug rebate cap, previously set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024
13. 65Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
14. 66federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products
15. 67recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry
16. 68If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
17. 69Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs

Risks Relating to Employee Matters and Managing Growth

1. 70Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain, and motivate qualified personnel
2. 71high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited
3. 72We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
4. 73Changes in tax law may adversely affect us or our investors
5. 74Our future taxable income may be subject to certain limitations
6. 75Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
7. 76Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements or insider trading
8. 77The market price of our common stock is expected to be volatile
9. 78period-to-period fluctuations in our financial results
10. 79We have incurred and will continue to incur increased costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies
11. 80Provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may discourage any takeover attempts our stockholders may consider favorable, and may lead to entrenchment of management
12. 81In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
13. 82We do not anticipate that we will pay any cash dividends in the foreseeable future
14. 83An active trading market for our common stock may not be sustained. If an active trading market is not sustained, our ability to raise capital in the future may be impaired
15. 84Future sales of shares by existing stockholders could cause our stock price to decline
16. 85Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
17. 86If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
18. 87We will have broad discretion in the use of our cash, cash equivalents, and marketable securities and may invest or spend our cash, cash equivalents, and marketable securities in ways with which you do not agree and in ways that may not increase the value of your investment